Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Circulating tumor DNA as a predictive biomarker in metastatic bladder cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 105 K
USD 80 K
Funding amount
Abstract
Metastatic bladder cancer is a lethal and under-studied disease. Chemotherapy has historically been the most effective treatment for metastatic disease, but long-term survival is rare. Exciting new treatment options have recently emerged, however, responses to these new therapies are highly variable and we lack a reliable method of predicting who the responders will be. Therefore, efforts are underway to develop tools to determine the ideal therapy for each individual based on their tumor's molecular features. My research aims to develop a blood-based test for identifying genetic changes (mutations) present in metastatic bladder tumors. This test relies on the fact that when cancer cells die they often shed their DNA into the circulating bloodstream (known as circulating tumor DNA, ctDNA). We can therefore use ctDNA to evaluate the mutations in metastatic cancers that correspond to treatment response or resistance. In my preliminary research, I found that most patients with metastatic bladder cancer can have their tumors analyzed in this manner. Importantly, my initial work showed that it was feasible for patients to have real-time testing of their cancer's molecular features, without the need for invasive tissue biopsy - which is often impractical, costly and can cause significant patient morbidity. In this project, I will identify mutations in the ctDNA of hundreds of Canadians with metastatic bladder cancer, and determine which mutations predict a patient's subsequent response to treatment. Success with my project will help explain why some metastatic bladder cancers are intrinsically responsive or resistant to the most commonly used therapies. Furthermore, I will have developed a clinically-practical framework (requiring only a blood sample) that may ultimately help guide rational therapy selection in advanced bladder cancer.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science